Church of PeptidesSearch
Portrait of Tesamorelin
Saint · FDA-approved · narrow indication

Tesamorelin

The Sculptor

Theratechnologies · Montreal, Canada · discovered 1995 · U.S. approval 2010

Tesamorelin stimulates the growth-hormone-releasing hormone pathway. Its approved role is to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, a specific indication that does not make it a general weight-loss medicine.

Evidence ladder: Approved human useApproved human use · product-specific labelsEducational record
ClassificationSaints
Evidence summaryApproved human use · product-specific labels
OriginTheratechnologies · Montreal, Canada · discovered 1995 · U.S. approval 2010
Scientific record

What the evidence says

Roles or demonstrated benefits

  • FDA-approved to reduce excess abdominal fat in adults with HIV and lipodystrophy.
  • Stimulates endogenous growth hormone through the GHRH receptor.
  • The demonstrated benefit is indication-specific—not general weight management.

Risks, side effects, and limits

  • Can cause glucose intolerance, elevated IGF-1, fluid retention, joint or muscle symptoms, and injection-site reactions.
  • Hypersensitivity can occur; the label includes contraindications and pregnancy warnings.
  • Long-term cardiovascular safety has not been established.
Doctide’s verdict

The Sculptor’s charter is specific: excess abdominal fat in adults with HIV and lipodystrophy. Doctide keeps the chisel inside that boundary; a reviewed indication does not validate broader physique or longevity claims.

Documented history

Where the story actually begins

The original EGRIFTA product received U.S. approval in 2010. Later development produced separate EGRIFTA formulations; the 2025 EGRIFTA WR label explicitly states that WR and SV are not substitutable, with different preparation and administration requirements. Historical source.

Theratechnologies · Montreal, Canada · discovered 1995 · U.S. approval 2010
Book of the Canon · Comic scripture

The laboratory legend

The Sculptor removed only what the charter permitted. Asked for general weight loss, she lowered her chisel and pointed silently to the exact wording carved above her bench.

This bold passage is invented comedy, not scientific or historical fact.
Editorial recordProfile editorial revision: October 4, 2026Prepared under the Church of Peptides evidence standardEditorial review: Church of PeptidesIndependent clinical review: none to dateContent evidence reviewed: September 12, 2026
Evidence ledger

Sources

  1. Theratechnologies history
  2. Current FDA label
  3. FDA summary review

Fiction disclosure: The bold laboratory legend above is invented. The historical and scientific sections are intended as sourced summaries; no invented connective events were added to the documented history.

Educational entertainment only. Not medical advice, diagnosis, dosing guidance, or a recommendation to obtain or use a product.